[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561164":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":16,"responsibleParty":98,"collaborators":10,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":10,"enrollmentInfo":110,"targetDuration":10,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":10},"Operable metastatic melanoma",null,[12],{"name":13,"role":14,"phone":10,"phoneExt":10,"email":15},"Charlée NARDIN, MD PhD","CONTACT","cnardin@chu-besancon.fr",[17,29,42,50,58,66,74,82,90],{"facility":18,"status":19,"city":20,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":10},"CHU Angers","ACTIVE_NOT_RECRUITING","Angers","France","FR",{"type":24,"coordinates":25},"Point",[26,27],-0.55202,47.47156,{"lat":27,"lon":26},{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":33,"geoPoint":37,"contacts":38},"CHU de Besançon","RECRUITING","Besançon",{"type":24,"coordinates":34},[35,36],6.01815,47.24878,{"lat":36,"lon":35},[39,40],{"name":13,"role":14,"phone":10,"phoneExt":10,"email":15},{"name":41,"role":14,"phone":10,"phoneExt":10,"email":10},"CHarlée NARDIN, MD PhD",{"facility":43,"status":19,"city":44,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":45,"geoPoint":49,"contacts":10},"Hôpital Avicenne","Bobigny",{"type":24,"coordinates":46},[47,48],2.45012,48.90982,{"lat":48,"lon":47},{"facility":51,"status":19,"city":52,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":53,"geoPoint":57,"contacts":10},"CH de Boulogne-sur-Mer","Boulogne-sur-Mer",{"type":24,"coordinates":54},[55,56],1.61373,50.72485,{"lat":56,"lon":55},{"facility":59,"status":19,"city":60,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"CHU Clermont-Ferrand","Clermont-Ferrand",{"type":24,"coordinates":62},[63,64],3.08682,45.77969,{"lat":64,"lon":63},{"facility":67,"status":19,"city":68,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Centre de Lutte Contre le Cancer Léon Bérard","Lyon",{"type":24,"coordinates":70},[71,72],4.84789,45.74906,{"lat":72,"lon":71},{"facility":75,"status":19,"city":76,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":77,"geoPoint":81,"contacts":10},"ICO René Gauducheau","Saint-Herblain",{"type":24,"coordinates":78},[79,80],-1.651,47.21154,{"lat":80,"lon":79},{"facility":83,"status":19,"city":84,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":85,"geoPoint":89,"contacts":10},"Institut Universitaire de Cancérologie de Toulouse","Toulouse",{"type":24,"coordinates":86},[87,88],1.44367,43.60426,{"lat":88,"lon":87},{"facility":91,"status":19,"city":92,"state":10,"zip":10,"country":21,"countryCode":22,"cosmosGeoPoint":93,"geoPoint":97,"contacts":10},"CH de Valence","Valence",{"type":24,"coordinates":94},[95,96],4.90956,44.9256,{"lat":96,"lon":95},{"type":99,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100561164","neoadjuvant-immunotherapy-of-operable-metastatic-melanoma-in-real-life-gcc-100561164",false,"NCT06586593","Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)","ETUDE NEOMEL: TRAITEMENT NEOADJUVANT PAR IMMUNOTHERAPIE DU MELANOME METASTATIQUE OPERABLE EN VIE REELLE (GCC)","NEOMEL","Inclusion Criteria:\n\n* Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \\[AJCC\\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\\'s refusal to be operated.\n* Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed\n\nExclusion Criteria:\n\n* Uveal melanoma","ALL","18 Years",{"count":111,"type":112},77,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.\n\nThe complete histological response will be assessed.",[116],"Melanoma Metastatic","2024-09-06",{"date":119,"type":120},"2024-09-19","ACTUAL",{"date":122,"type":120},"2023-03-24",{"date":124,"type":112},"2025-01",{"name":5,"class":6},9]